![](https://porib.com/wp-content/uploads/2021/07/clinical_drug_investigation-1.jpg)
Quintero J, Oyagüez I, González B, Cuervo-Arango I, García I, Casado MA
Cost-minimisation analysis of paliperidone palmitate long-acting treatment versus risperidone long-acting treatment for schizophrenia in Spain
Clin Drug Investig. 2016;36(3):479-90
![](https://porib.com/wp-content/uploads/2021/07/heroin_addiction_and_related_clinical_problems.jpg)
Carrera I, Sanchez L, Sabater E, Pereiro C, Florez G, Conde M, Pino C, Serrano M, Casado MA, for the TSO-Galicia Group
Study on users’ perception of opiate substitution treatment in the Galician network of drug addiction
Heroin Addict Relat Clin Probl 2016; 18(3): 29-42
![](https://porib.com/wp-content/uploads/2021/07/rheumatology_international.jpg)
Cárdenas M, de la Fuente S, Font P, Castro-Villegas MC, Romero-Gómez M, Ruiz-Vílchez D, Calvo-Gutiérez J, Escudero-Contreras A, Casado MA, Del Prado JR, Collantes E
Real-world effectiveness and efficiency of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: Results of the CREATE registry
Rheumatology International 2016; 36:231-241
![](https://porib.com/wp-content/uploads/2021/07/clinical_drug_investigation.jpg)
Rodríguez González-Moro JM, Menéndez R, Campins M, Lwoff N, Oyagüez I, Echave M, Rejas J, Antoñanzas F
Cost-effectiveness of 13-valent conjugate pneumococcal vaccination program in COPD patients aged 50+ years in Spain
Clin Drug Investig. 2016;36:41-53
![](https://porib.com/wp-content/uploads/2021/06/pharmacoeconomics_spanish_research_articles-1.jpg)
Valor L, Díaz-Cerezo S, López-Lacey A, Martínez-Arroyo AM, Casado MA, Carreño L
El valor de las terapias biológicas en el tratamiento de las enfermedades reumáticas crónicas. Una revisión sistemática de su evidencia farmacoeconomica en España
Pharmacoecon Span Res Artic. 2016;13:69–89
![](https://porib.com/wp-content/uploads/2021/07/reumatologia_clinica.jpg)
Roman Ivorra JA, Ivorra J, Monte-Bouquet E, Canal C, Oyagüez I, Gómez-Barrera M
Análisis de costes de la utilización de fármacos biológicos para la artritis reumatoide en primera línea de tratamiento tras respuesta inadecuada a metotrexato en función del peso de los pacientes
Reumatol Clin 2016;12(3):123-9
![](https://porib.com/wp-content/uploads/2021/07/semergen.jpg)
De Lossada A, Oteo A, Giménez S, Oyagüez I, Rejas J
Análisis coste-efectividad de celecoxib frente a antiinflamatorios no esteroideos no selectivos en el tratamiento de la artrosis en España: Una perspectiva actual
Semergen 2016;42:235-43
![](https://porib.com/wp-content/uploads/2021/07/international_journal_of_chronic_obstructive_pulmonary_disase.jpg)
Jiménez-Ruiz CA, Solano-Reina S, Signes-Costa J, de Higes-Martinez E, Granda-Orive JI, Lorza-Blasco JJ, Riesco-Miranda JA, Altet-Gomez N, Barrueco-Ferrero M, Oyagüez I, Rejas J
Budgetary Impact Analysis on Funding Smoking-cessation Drugs in Patients with Chronic Obstructive Pulmonary Disease in Spain
Int J Chron Obstruct Pulmon Dis. 2015;10:2027-36
![](https://porib.com/wp-content/uploads/2021/07/health_economics_review-2.jpg)
Gros B, Galan A, Gonzalez-Parra E, Herrero JA, Echave M, Vegter S, Tolley K, Oyagüez I
Cost effectiveness of Lanthanum Carbonate in chronic kidney disease patients in Spain before and during dialysis
Health Econ Rev. 2015;5:14 doi:10.1186/s13561-015-0049-3
![](https://porib.com/wp-content/uploads/2021/07/plos_one-1.jpg)
Romero-Gómez M, Turnes J, Ampuero J, Oyagüez I, Cuenca B, González-García J, Muñoz-Molina B, Aguilar R, Leal S, Planas R, García-Samaniego J, Diago M, Crespo J, Calleja JL, Casado MA, Solà R